Free Trial

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 4.9% - Time to Sell?

Solid Biosciences logo with Medical background
Remove Ads

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) dropped 4.9% during trading on Monday . The stock traded as low as $5.03 and last traded at $5.16. Approximately 377,782 shares changed hands during trading, a decline of 87% from the average daily volume of 2,873,468 shares. The stock had previously closed at $5.42.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Truist Financial initiated coverage on Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price on the stock. Wedbush assumed coverage on Solid Biosciences in a research note on Friday, December 13th. They issued an "outperform" rating and a $16.00 price target on the stock. JMP Securities started coverage on Solid Biosciences in a research note on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective on the stock. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday. Nine investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $15.70.

View Our Latest Report on SLDB

Solid Biosciences Stock Up 0.1 %

The business has a 50-day moving average price of $4.18 and a 200-day moving average price of $5.47. The company has a market capitalization of $399.48 million, a price-to-earnings ratio of -1.68 and a beta of 1.98.

Remove Ads

Institutional Trading of Solid Biosciences

Several large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Solid Biosciences in the third quarter worth approximately $293,000. Valence8 US LP bought a new stake in Solid Biosciences during the third quarter worth approximately $110,000. The Manufacturers Life Insurance Company acquired a new position in Solid Biosciences in the 3rd quarter valued at $71,000. FMR LLC bought a new position in shares of Solid Biosciences in the third quarter worth about $305,000. Finally, MetLife Investment Management LLC lifted its holdings in shares of Solid Biosciences by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,699 shares of the company's stock worth $95,000 after buying an additional 7,719 shares during the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

(Get Free Report)

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

See Also

Should You Invest $1,000 in Solid Biosciences Right Now?

Before you consider Solid Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.

While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads